Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 7/20 | 0.42 |
| ▸ | CES1 | P23141 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20654846 | 1.00 | CES2 (0.58) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL31190467 | 1.00 | CES2 (0.58) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL20654753 | 1.00 | CES2 (0.58) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL8863676 | 1.00 | CES2 (0.58) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL9495469 | 1.00 | CES2 (0.58) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL23578179 | 1.00 | CES2 (0.58) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL15059581 | 0.98 | CES2 (0.55) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL1619413 | 0.92 | CES2 (0.47) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL27351978 | 0.92 | CYP4F2 (0.50) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL20654768 | 0.87 | CYP4F2 (0.66) | CES2MEN1KMT2AMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107556192-B | Method for synthesizing ethyl 2, 2-difluorohexanoate | 南京大学 | 2021-01-15 | — | — | CN | disclosed |
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2760820-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | Emory University (US) | 2014-08-06 | — | — | EP | disclosed |
| CN-103958457-A | Sphingosine analogs, compositions, and methods related thereto | UNIV EMORY | 2014-07-30 | — | — | CN | disclosed |
| WO-2013049280-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049280-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-0525479-B1 | Spicamycin derivatives and the use thereof | KIRIN BREWERY (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5631238-A | ANTICARCINOGENIC AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1997-05-20 | — | — | US | disclosed |
| US-5461036-A | Treating colon, gastric, esophageal cancer | KIRIN BEER KABUSHIKI KAISHA (JP) | 1995-10-24 | — | — | US | disclosed |
| EP-0525479-A1 | Spicamycin derivatives and the use thereof | KIRIN BEER KABUSHIKI KAISHA (JP) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | SPHK1, S1PR1, S1PR2 | CES2 1647/4885MEN1 245/4885KMT2A 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.